C
Causaly
A biomedical research discovery tool that makes it simple to find and unlock key hidden evidence to make new predictions in biomedical science
About Causaly
Causaly is a startup that operates in the field of artificial intelligence (AI) and research and development (R&D). The company offers AI solutions that significantly enhance research productivity by reducing the time spent on reading scientific literature. This is achieved through a high-precision, high-accuracy search tool that sifts through the ever-increasing volume of scientific documents, enabling users to discover new insights and make unbiased decisions with confidence.
Read full description
Causaly's AI has machine-read over 40 million scientific documents, creating a network of more than 350 million directional relationships connecting diseases, pathways, and genes. This vast network allows for a new dimension in scientific exploration and hypothesis generation.
The company's primary clients are pharmaceutical companies, with 12 out of the top 20 pharma companies using Causaly's services to understand disease biology, identify novel targets, and discover biomarkers. The platform is designed to be highly visual and intuitive, requiring no technical expertise to use.
Causaly also assists in the management of the exponential growth of biomedical data, reducing bias and separating signal from noise. This human-centric AI solution can boost research productivity by up to 90%, allowing teams to pursue a more innovative and exploratory direction in drug discovery.
The company makes money by offering its AI solutions to pharmaceutical and biomedical research and development teams. By accelerating the identification and selection of promising biomarkers, Causaly helps to speed up the approval process, saving its clients time and money.
At a glance
- Founded
- 2018
- Headquarters
- London, United Kingdom
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning Causaly.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed5 investors entered at this stage
Marathon Venture Capital
Matt Clifford
Charlie Songhurst
Nadav Rosenberg
Emerge VC
Series A7 investors entered at this stage
Pentech Ventures
European Bank for Reconstruction and Development
Index Ventures
ICONIQ Growth
Olivier Pomel
Alex Gorsky
Visionaries
Series B and later4 investors entered at this stage
- ICONIQ Growth
- VIVisionaries
- OPOlivier Pomel
- AGAlex Gorsky
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Causaly on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Causaly on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.